Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Guay

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Bioorganic & Medicinal Chemistry Letters|August 28, 1999
SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitorY Leblanc, P Roy, S Boyce, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 1999
Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitorsC K Lau, C Brideau, C C Chan, et al.
Journal of Medicinal Chemistry|April 10, 1999
2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitorsW C Black, C Brideau, C C Chan, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 1999
A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitorsC S Li, W C Black, C Brideau, et al.
Journal of Medicinal Chemistry|September 27, 1996
Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stabilityD Delorme, Y Ducharme, C Brideau, et al.
Journal of Medicinal Chemistry|August 29, 1997
Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010P Hamel, D Riendeau, C Brideau, et al.
British Journal of Pharmacology|May 1, 1997
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitorD Riendeau, M D Percival, S Boyce, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profilesC C Chan, S Boyce, C Brideau, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2D Riendeau, M D Percival, C Brideau, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Bioorganic & Medicinal Chemistry Letters|August 28, 1999
SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitorY Leblanc, P Roy, S Boyce, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 1999
Synthesis and biological evaluation of 3-heteroaryloxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitorsC K Lau, C Brideau, C C Chan, et al.
Journal of Medicinal Chemistry|April 10, 1999
2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitorsW C Black, C Brideau, C C Chan, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 1999
A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitorsC S Li, W C Black, C Brideau, et al.
Journal of Medicinal Chemistry|September 27, 1996
Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stabilityD Delorme, Y Ducharme, C Brideau, et al.
Journal of Medicinal Chemistry|August 29, 1997
Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010P Hamel, D Riendeau, C Brideau, et al.
British Journal of Pharmacology|May 1, 1997
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitorD Riendeau, M D Percival, S Boyce, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profilesC C Chan, S Boyce, C Brideau, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2D Riendeau, M D Percival, C Brideau, et al.
Pageof 7